Tadalafil Market is expected to grow at a significant CAGR during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in December 2020, Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global pharmaceutical company, received final approval from the US Food and Drug Administration (US FDA) for Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, the generic version of Eli Lilly and Company's Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. The Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg market had annual sales of approximately $125.5 million, for the 12-month period ending November 2020.
In September 2021, IntelGenx Corp. announced that Aquestive Therapeutics, Inc., its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), has signed a definitive license and supply agreement. Securing this commercial relationship is a critical milestone in creative collaboration with Aquestive, and it represents yet another big step toward realising the shared objective of making Tadalafil oral films available to men suffering from ED and BP. In February 2019, Teva Pharmaceutical Industries Ltd. announced the launch of ALYQ in the US, a generic version of ADCIRCA (tadalafil) tablets, 20 mg. ALYQ is a phosphodiesterase 5 (PDE5) inhibitor used to improve exercise performance in people with pulmonary arterial hypertension (PAH). High blood pressure in the lungs' blood arteries is known as PAH. Teva has the largest portfolio of FDA-approved generic pharmaceuticals on the market, with over 550 generic medications accessible, and is the market leader in first-to-file opportunities, with over 100 pending first-to-files in the US. Teva generics are being used to satisfy one out of every seven generic prescriptions written in the US. In the US, ADCIRCA generated roughly $490 million in annual sales in November 2018.
To Request a Sample of our Report on Tadalafil Market: https://www.omrglobal.com/request-sample/tadalafil-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
By Product
By Application
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Glenmark Pharmaceuticals Ltd., Eli, Lilly & Co., and Teva Pharmaceutical Industries Ltd., among others.
Tadalafil Market Report by Segment
By Type
- Purity:98%
- Purity: >98%
By Application
- Erectile Dysfunction
- Benign Prostatic Hyperplasia
- Others
A full Report of Tadalafil Market is Available @ https://www.omrglobal.com/industry-reports/tadalafil-market
Tadalafil Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404